Web29 ott 2012 · jcog0505試験の対象症例については、主な適格基準として、扁平上皮癌(scc)または腺癌(non-scc)、局所制御不能な遠隔転移を有するか骨盤内に ... WebINTERLACE試験 82, 86, 136 interstitial brachytherapy 46 intracavitary brachytherapy (ICBT) 45 IP療法 164 J JACCRO-GY-01試験 134 JCOG0102試験 82, 89 JCOG0505試験 142, 165 JCOG1101試験 79 JGOG1065試験 82, 86, 89 JGOG1066試験 82, 130, 133, 134 JO29569試験 166 K Kansai Clinical Oncology Group(KCOG) 111 L
Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin …
WebPurpose: The Japan Clinical Oncology Group (JCOG) trial JCOG0505 demonstrated the statistically significant non-inferiority of paclitaxel plus carboplatin (TC) to paclitaxel plus cisplatin (TP) in terms of overall survival (OS) in metastatic or recurrent cervical cancer. In that trial, patients were randomly assigned, adjusting for institution and known prognostic … Web12 ott 2009 · PROTOCOL DIGEST OF THE JCOG0505 Trial Backgrounds The prognosis of patients with metastatic, recurrent or persistent cervical cancer who are not amenable to curative treatment with surgery and/or radiation therapy is still poor. Therefore, systemic chemotherapy is currently regarded as a key modality that should be further developed. kough feed service cherry tree pa
JISK0550:1994 超純水中の細菌数試験方法
Web20 mag 2012 · 5006 Background: TC is a less toxic regimen in terms of milder nephropathy, neuropathy and no need of hospitalization. This multicenter phase III trial was designed to evaluate the clinical benefits of TC compared with TP which is current standard chemotherapy for stage IVB or recurrent cervical cancer. Methods: Patients (pts) with … http://www.jcog.jp/document/0505.pdf WebJ-GLOBAL ID:201302253285062497 整理番号:13A1179657 進行・再発子宮頸癌に対する化学療法 (JCOG0505試験結果および今後の展開) 出版者サイト 複写サービス 高度な検索・分析はJDreamⅢで 著者 (1件): 喜多川亮 ( NTT東日本 関東病院 産婦人科 ) 資料名: 日本婦人科腫瘍学会雑誌 (日本婦人科腫よう学会雑誌) 巻: 31 号: 3 ページ: 356-357 … mansfield state high facebook